|Day's Range||28.07 - 29.08|
|52 Week Range||28.07 - 56.44|
|PE Ratio (TTM)||371.79|
|Dividend & Yield||1.36 (4.62%)|
|1y Target Est||N/A|
In 1Q17, Neupogen generated revenues of ~$148 million, a significant drop from the drug’s 1Q16 revenues of ~$213 million.
Teva Pharmaceuticals has experienced a rough year, but the stock could be bottoming out at current levels.
Commenting on Mylan N.V. (NASDAQ: MYL ), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. ...